Table 5.

Pathological characteristics of the tumours in breast cancer patients with NOD2 mutation according to age

Risk factor		NOD2 < 50 years (n = 68)		NOD2 ≥ 50 years (n = 82)		NOD2 < 50 years vs. NOD2 ≥ 50 years	p
		n	%	n	%	OR
Clinical staging nodes
	N positive	25	36.8	27	32.9	1.18	0.749
	N negative	43	63.2	55	67.1	1
Tumour size
	T3–4	11	16.2	5	6.1	2.97	0.063
	T1–2	57	83.8	77	93.9	1
Grade G
	G3	27	39.7	14	17.1	3.20	0.004
	G1 + G2	41	60.3	68	82.9	1
ER
	Negative	16	23.5	13	15.9	1.63	0.328
	Positive	52	76.5	69	84.1	1
PR
	Negative	21	30.9	19	23.2	1.48	0.380
	Positive	47	69.1	63	76.8	1
HER2 overexpression
	Positive	15	22.1	8	9.8	2.62	0.043
	Negative	53	77.9	74	90.2	1
Molecular subtype
	Luminal A & B– type	41	60.3	64	78.0	0.43	0.029
	Others	27	39.7	18	22.0	1
Triple negative
	Yes	12	17.6	10	12.2	1.54	0.479
	No	56	82.4	72	87.8	1
Molecular subtype
	Luminal A type	18	26.5	40	48.8	1
	Luminal B– type	23	33.8	24	29.3	2.13	0.095
	Luminal B+ type	11	16.2	5	6.1	4.89	0.009
	Triple negative	12	17.6	10	12.2	2.67	0.093
	Non luminal	4	5.9	3	3.7	2.96	0.215